Solventum Corp Q1 FY2025 earnings call

Key Points

• Bryan Hanson noted a strong start in 2025, raised organic revenue guidance, and addressed tariffs, stating tariffs are a headwind but mitigations are in place.
• Wayde McMillan provided a separation update, Q1 financial details, and 2025 guidance, including tariff impact.

Transformation Plan

• Phase I: Mission/values deployed globally, talent hired, separation on track.
• Phase II: Aligned on long-range plan and focusing on 5 growth drivers.
• Phase III: Anticipates tuck-in M&A after P&F divestiture.

Segment Highlights

• MedSurg: Strong quarter with V.A.C Peel and Place success, IV side management growth, and US capacity expansion.
• Dental Solutions: Benefited from core restoratives, aesthetics, and new product launches.
• HIS: Focus on revenue cycle management and autonomous coating.
• Purification & Filtration: Robust demand in bioprocessing and industrial filtration, but membranes declined.

MedSurg: Delivered $1.2 billion of sales, an increase of 6% on an organic basis. Dental Solutions: Generated $328 million of revenue, a 0.4% increase on an organic basis. Health Information Systems: Contributed $329 million of revenue, a 3.9% increase on an organic basis. Purification & Filtration: Delivered $242 million of sales, a 2.2% increase on an organic basis.

Revenue Guidance

• Raised organic revenue guidance to a range of 1.5% to 2.5%.

EPS and Tariffs

• Maintained EPS guidance of $5.45 to $5.65, with tariff headwinds estimated at $80 million to $100 million (EPS impact $0.35 to $0.45).

Operating Margins

• Operating margins expected at the low end of the 20% to 21% range.

Free Cash Flow

• Free cash flow guidance remains $450 million to $550 million.

• Tariffs pose a headwind, with evolving trade policies creating uncertainty. The fluid nature of tariff situations requires ongoing monitoring and mitigation efforts.

Q: How confident are you around the 2.5% underlying growth?

A: Wayde McMillan stated they're confident, noting it's an estimate but based on analytics and understanding of customer order patterns.

Q: Can you help with quarterly cadence considering tariffs and business momentum?

A: Bryan Hanson clarified tariffs have minimal top-line impact, with order timing effects from ERP cutovers and plant changes impacting Q3 mostly.

Q: How does the 2.5% underlying growth compare to internal expectations?

A: Bryan Hanson said it was above expectations, driven by enhanced commercial organization focus and new product launches.

Q: Unpack drivers in MedSurg?

A: Bryan Hanson cited commercial execution improvements, existing strong brands, and new product launches like V.A.C Peel and Place.

Q: How are tariffs being mitigated?

A: Wayde McMillan mentioned strong business performance, favorable FX, inventory optimization, sourcing strategies, and selective pricing.

Q: Clarification on EU tariff assumptions and annualizing impact?

A: Bryan Hanson stated EU tariffs at 10% are assumed to stay, and annualizing the tariff impact is difficult due to evolving mitigation and timing.

Q: How did Dental perform relative to market?

A: Bryan Hanson said Dental performed well in resilient categories, with new innovation providing tailwind.

Q: How much of tariff impact is tied to P&F?

A: Wayde McMillan said they're not breaking it out, guiding for the whole company with P&F still a holdco, and phasing impacts across quarters.